RESUMO
INTRODUCTION AND OBJECTIVES: Autoimmune liver diseases (AILDs): autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC) have different survival outcomes after liver transplant (LT). Outcomes are influenced by factors including disease burden, medical comorbidities, and socioeconomic variables. MATERIALS AND METHODS: Using the United Network for Organ Sharing database (UNOS), we identified 13,702 patients with AILDs listed for LT between 2002 and 2021. Outcomes of interest were waitlist removal, post-LT patient survival, and post- LT graft survival. A stepwise multivariate analysis was performed adjusting for transplant recipient gender, race, diabetes mellitus, model for end-stage liver disease (MELD) score, and additional social determinants including the presence of education, reliance on public insurance, working for income, and U.S. citizenship status. RESULTS: Lack of college education and having public insurance increased the risk of waitlist removal (HR, 1.13; 95 % CI, 1.05-1.23, and HR, 1.09; 95 % CI, 1.00-1.18; respectively), and negatively influenced post-LT patient survival (HR, 1.16; 95 % CI, 1.06-1.26, and HR, 1.15; 95 % CI, 1.06-1.25; respectively) and graft survival (HR, 1.13; 95 % CI, 1.05-1.23, and HR, 1.15; 95 % CI, 1.06-1.25; respectively). Not working for income proved to have the greatest detrimental impact on both patient survival (HR, 1.41; 95 % CI, 1.24-1.6) and graft survival (HR, 1.21; 95 % CI, 1.09-1.35). CONCLUSIONS: Our study highlights that lack of college education and public insurance have a detrimental impact on waitlist mortality, patient survival, and graft survival. Not working for income negatively affects post-LT survival outcomes. Not having U.S. citizenship does not affect survival outcomes in AILDs patients.
Assuntos
Sobrevivência de Enxerto , Hepatite Autoimune , Transplante de Fígado , Fatores Socioeconômicos , Humanos , Masculino , Feminino , Estados Unidos/epidemiologia , Pessoa de Meia-Idade , Hepatite Autoimune/mortalidade , Hepatite Autoimune/cirurgia , Adulto , Colangite Esclerosante/cirurgia , Colangite Esclerosante/mortalidade , Listas de Espera/mortalidade , Cirrose Hepática Biliar/cirurgia , Cirrose Hepática Biliar/mortalidade , Fatores de Risco , Bases de Dados Factuais , Idoso , Escolaridade , Fatores de TempoRESUMO
BACKGROUND: The influence of sex on primary sclerosing cholangitis (PSC), pre- and postliver transplantation (LT) is unclear. Aims are to assess whether there have been changes in incidence, profile, and outcome in LT-PSC patients in Europe with specific emphasis on sex. METHODS: Analysis of the European Liver Transplant Registry database (PSC patients registered before 2018), including baseline demographics, donor, biochemical, and clinical data at LT, immunosuppression, and outcome. RESULTS: European Liver Transplant Registry analysis (n = 6463, 32% female individuals) demonstrated an increasing number by cohort (1980-1989, n = 159; 1990-1999, n = 1282; 2000-2009, n = 2316; 2010-2017, n = 2549) representing on average 4% of all transplant indications. This increase was more pronounced in women (from 1.8% in the first cohort to 4.3% in the last cohort). Graft survival rate at 1, 5, 10, 15, 20, and 30 y was 83.6%, 70.8%, 57.7%, 44.9%, 30.8%, and 11.6%, respectively. Variables independently associated with worse survival were male sex, donor and recipient age, cholangiocarcinoma at LT, nondonation after brain death donor, and reduced size of the graft. These findings were confirmed using a more recent LT population closer to the current standard of care (LT after the y 2000). CONCLUSIONS: An increasing number of PSC patients, particularly women, are being transplanted in European countries with better graft outcomes in female recipients. Other variables impacting outcome include donor and recipient age, cholangiocarcinoma, nondonation after brain death donor, and reduced graft size.
Assuntos
Colangite Esclerosante/cirurgia , Sobrevivência de Enxerto , Disparidades nos Níveis de Saúde , Disparidades em Assistência à Saúde/tendências , Transplante de Fígado/tendências , Adulto , Colangite Esclerosante/diagnóstico , Colangite Esclerosante/epidemiologia , Bases de Dados Factuais , Europa (Continente)/epidemiologia , Feminino , Humanos , Incidência , Transplante de Fígado/efeitos adversos , Masculino , Pessoa de Meia-Idade , Sistema de Registros , Medição de Risco , Fatores de Risco , Fatores Sexuais , Fatores de Tempo , Resultado do TratamentoRESUMO
BACKGROUND: This study investigated the impact of Model of end-stage liver disease (MELD)-score introduction (MELDi) on waitlist mortality and post-liver transplant (LT) survival in primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). METHODS: LT candidates with PSC or PBC listed between January 1983 and March 2016 were included and followed until December 2016. After MELDi in 2004, PBC patients were listed according to labMELD, PSC patients according to the highest MELD during active cholangitis (chMELD). RESULTS: In total, 100 PBC and 76 PSC patients were included. Waitlist mortality in PBC was significantly higher than in PSC (16% vs. 5.3%, p = 0.031), whereas PSC patients were significantly more often withdrawn from the waitlist due to improved condition (3.0% vs. 13.2%, p = 0.017). Competing risks analysis identified MELDi (HR = 4.12) and PBC (HR = 2.95) as significant predictors of waitlist mortality. Yet, overall 10 y-patient survival increased after MELDi by 18.8% leading to a 1 y-, 5 y-, and 10 y-patient survival of 98.2%, 70.6% and 70.6% in PBC, and 83.3%, 83.3%, and 80.6% in PSC, respectively. CONCLUSIONS: PSC patients showed significantly lower waitlist mortality irrespective of MELDi, whereas in PBC waitlist mortality further increased after MELDi. Utility of MELD and chMELD did not impair post LT outcome.
Assuntos
Colangite Esclerosante/cirurgia , Cirrose Hepática Biliar/cirurgia , Transplante de Fígado , Formulação de Políticas , Obtenção de Tecidos e Órgãos/organização & administração , Listas de Espera/mortalidade , Adulto , Áustria , Colangite Esclerosante/diagnóstico , Colangite Esclerosante/mortalidade , Tomada de Decisão Clínica , Técnicas de Apoio para a Decisão , Feminino , Sobrevivência de Enxerto , Humanos , Cirrose Hepática Biliar/diagnóstico , Cirrose Hepática Biliar/mortalidade , Transplante de Fígado/efeitos adversos , Transplante de Fígado/mortalidade , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias/mortalidade , Medição de Risco , Fatores de Risco , Fatores de Tempo , Resultado do TratamentoRESUMO
Studies from the USA and Nordic countries indicate primary sclerosing cholangitis (PSC) patients have low mortality on the liver transplantation (LTx) waiting list. However, this may vary among geographical areas. Therefore, we compared waiting list mortality and post-transplant survival between laboratory model for end-stage liver disease (LM) and MELD exception (ME)-prioritized PSC and non-PSC candidates in a nationwide study in the Netherlands. A retrospective analysis of patients waitlisted from 2006 to 2013 was conducted. A total of 852 candidates (146 PSC) were waitlisted of whom 609 (71.5%) underwent LTx and 159 (18.7%) died before transplantation. None of the ME PSC patients died, and they had a higher probability of LTx than LM PSC [HR obtained by considering ME as a time-dependent covariate (HRME 9.86; 95% CI 6.14-15.85)] and ME non-PSC patients (HRME 4.60; 95% CI 3.78-5.61). After liver transplantation, PSC patients alive at 3 years of follow-up had a higher probability of relisting than non-PSC patients (HR 7.94; 95% CI 1.98-31.85) but a significantly lower mortality (HR 0.51; 95% CI 0.27-0.95). In conclusion, current LTx prioritization advantages PSC patients on the LTx waiting list. Receiving ME points is strongly associated with timely LTx.
Assuntos
Colangite Esclerosante/cirurgia , Política de Saúde , Falência Hepática/cirurgia , Transplante de Fígado/métodos , Obtenção de Tecidos e Órgãos/métodos , Listas de Espera , Adulto , Feminino , Sobrevivência de Enxerto , Humanos , Masculino , Pessoa de Meia-Idade , Países Baixos , Probabilidade , Estudos Retrospectivos , Medição de Risco , Fatores de Tempo , Doadores de TecidosRESUMO
PURPOSE: The chronic liver disease questionnaire (CLDQ) is a frequently used liver-specific quality of life instrument, but it does not provide information on preference-adjusted health status, which is essential for cost-utility analysis. We aimed to develop a mapping function deriving utilities from the CLDQ in primary sclerosing cholangitis (PSC). METHODS: Short form-6D (SF-6D) utilities were calculated from SF-36 data collected in a recent prospective study in which unselected patients with PSC also completed the CLDQ. Ordinary least squares (OLS), generalized linear, median, and kernel regression analyses were employed to devise a mapping function predicting utilities. This was validated in three random subsamples of the cohort and in a separate sample of PSC patients following liver transplantation. Adjusted R (2) and root-mean-square error (RMSE) as well as Pearson's r coefficients and mean absolute errors between predicted and observed values were used to determine model performance. RESULTS: Decompensated liver disease and fatigue, systemic symptoms, and emotional distress, assessed with the CLDQ, were related to worse SF-6D utilities. The final OLS prediction model explained 66.3 % of the variance in the derivation sample. Predicted and observed utilities were strongly correlated (r = 0.807, p < 0.001), but the mean absolute error (0.0604) and adjusted RMSE (10.6 %) were of intermediate size. Similar model characteristics were observed after employment of generalized linear and median regression models and at validation. CONCLUSIONS: A model has been constructed, showing good validity predicting SF-6D utilities from CLDQ scores at the group level in PSC. Further testing is required to externally validate the model.
Assuntos
Algoritmos , Colangite Esclerosante/psicologia , Nível de Saúde , Hepatopatias/psicologia , Qualidade de Vida/psicologia , Inquéritos e Questionários , Colangite Esclerosante/cirurgia , Análise Custo-Benefício , Feminino , Humanos , Análise dos Mínimos Quadrados , Hepatopatias/cirurgia , Transplante de Fígado , Masculino , Pessoa de Meia-Idade , Modelos Teóricos , Estudos ProspectivosRESUMO
BACKGROUND/AIMS: The aim of this study was to compare the utility of the revised Mayo risk model (rMRM) and Child-Pugh scores (CPSs) for predicting the prognosis of disease in patients with primary sclerosing cholangitis (PSC). MATERIALS AND METHODS: Patients were divided into 2 groups: Group I (37 patients; alive and not requiring liver transplantation) and Group II (8 patients; deceased or requiring liver transplantation). rMRM suggests the possible survival percentage over a 4-year period. Thus, rMRM scores and CPSs on the first visit were calculated from the data at the time of diagnosis for patients diagnosed with PSC <4 years ago. rMRM scores and CPSs of patients with >4 years of follow-up were calculated using data from the visit 4 years prior to their last follow-up. RESULTS: Bivariate analyses showed that need for liver transplantation/mortality was correlated with either first visit CPS (r=0.481, p=0.001) or rMRM (r=0.452, p=0.002). Analysis of the area under the curve showed that both models performed similarly in terms of predicting the need for liver transplantation/mortality (rMRM: 0.780; CPS: 0.762; p=0.8). There was a significant difference in Kaplan-Meier survival rates between Group I and Group II for both risk models (rMRM: p<0.001; CPS: p<0.001) when the decisive event was death or need for liver transplantation. CONCLUSION: Both rMRM and CPSs are useful in risk assessment of patients with PSC. The ability to predict prognosis is similar for both risk models.
Assuntos
Colangite Esclerosante/classificação , Colangite Esclerosante/cirurgia , Transplante de Fígado , Modelos Teóricos , Adolescente , Adulto , Idade de Início , Idoso , Área Sob a Curva , Colangite Esclerosante/mortalidade , Feminino , Humanos , Estimativa de Kaplan-Meier , Masculino , Pessoa de Meia-Idade , Prognóstico , Medição de Risco/métodos , Adulto JovemRESUMO
Historically, liver biopsy has been used to determine the etiology of liver disease, the degree of inflammation, the stage of liver fibrosis, and the response to treatments. In the last decade, the advent of noninvasive tests has improved the diagnosis and management of autoimmune liver diseases. For example, serum markers can identify hepatic inflammation, whereas ultrasound and MRI can diagnose liver fibrosis. Physicians now have a much larger repertoire of diagnostic tests to assess the liver parenchyma compared with liver biopsy alone. In some rare cases, noninvasive tests may provide an alternative to liver biopsy. In general, however, these noninvasive tests complement liver biopsy and provide quick, accurate, and reliable adjunctive data.
Assuntos
Autoanticorpos/sangue , Autoimunidade , Colangite Esclerosante/diagnóstico , Diagnóstico por Imagem , Hepatite Autoimune/diagnóstico , Cirrose Hepática Biliar/diagnóstico , Fígado , Animais , Biomarcadores/sangue , Biópsia , Colangite Esclerosante/sangue , Colangite Esclerosante/imunologia , Colangite Esclerosante/patologia , Colangite Esclerosante/cirurgia , Diagnóstico por Imagem/métodos , Hepatite Autoimune/sangue , Hepatite Autoimune/imunologia , Hepatite Autoimune/patologia , Hepatite Autoimune/cirurgia , Humanos , Fígado/diagnóstico por imagem , Fígado/imunologia , Fígado/metabolismo , Fígado/patologia , Fígado/cirurgia , Cirrose Hepática Biliar/sangue , Cirrose Hepática Biliar/imunologia , Cirrose Hepática Biliar/patologia , Cirrose Hepática Biliar/cirurgia , Transplante de Fígado/efeitos adversos , Imageamento por Ressonância Magnética , Valor Preditivo dos Testes , Recidiva , Índice de Gravidade de Doença , Resultado do Tratamento , UltrassonografiaRESUMO
Cost issues in liver transplantation (LT) have received increasing attention, but the cost-utility is rarely calculated. We compared costs per quality-adjusted life year (QALY) from the time of placement on the LT waiting list to 1 year after transplantation for 252 LT patients and to 5 years after transplantation for 81 patients. We performed separate calculations for chronic liver disease (CLD), acute liver failure (ALF), and different Model for End-Stage Liver Disease (MELD) scores. For the estimation of QALYs, the health-related quality of life was measured with the 15D instrument. The median costs and QALYs after LT were 141,768 and 0.895 for 1 year and 177,618 and 3.960 for 5 years, respectively. The costs of the first year were 80% of the 5-year costs. The main cost during years 2 to 5 was immunosuppression drugs (59% of the annual costs). The cost/QALY ratio improved from 158,400/QALY at 1 year to 44,854/QALY at 5 years, and the ratio was more beneficial for CLD patients (42,500/QALY) versus ALF patients (63,957/QALY) and for patients with low MELD scores versus patients with high MELD scores. Although patients with CLD and MELD scores > 25 demonstrated markedly higher 5-year costs (228,434) than patients with MELD scores < 15 (169,541), the cost/QALY difference was less pronounced (59,894/QALY and 41,769/QALY, respectively). The cost/QALY ratio for LT appears favorable, but it is dependent on the assessed time period and the severity of the liver disease.
Assuntos
Custos de Cuidados de Saúde/estatística & dados numéricos , Falência Hepática , Transplante de Fígado/economia , Transplante de Fígado/mortalidade , Qualidade de Vida , Anos de Vida Ajustados por Qualidade de Vida , Adulto , Colangite Esclerosante/economia , Colangite Esclerosante/mortalidade , Colangite Esclerosante/cirurgia , Análise Custo-Benefício/economia , Análise Custo-Benefício/estatística & dados numéricos , Custos de Medicamentos/estatística & dados numéricos , Feminino , Finlândia/epidemiologia , Humanos , Imunossupressores/economia , Cirrose Hepática Biliar/economia , Cirrose Hepática Biliar/mortalidade , Cirrose Hepática Biliar/cirurgia , Hepatopatias Alcoólicas/economia , Hepatopatias Alcoólicas/mortalidade , Hepatopatias Alcoólicas/cirurgia , Falência Hepática/economia , Falência Hepática/mortalidade , Falência Hepática/cirurgia , Masculino , Pessoa de Meia-Idade , Modelos EstatísticosRESUMO
BACKGROUND: Use of the Model for End-Stage Liver Disease (MELD) score has improved the efficiency of allocating deceased donor organs for liver transplant. However, its use may reduce access to deceased donor livers for patients with primary sclerosing cholangitis (PSC) due to the weighting of the MELD score variables. To overcome such barriers in the post-MELD era, clinicians might refer patients with PSC, relative to patients without PSC, for living donor transplants more frequently. METHODS: To test this hypothesis, we examined patients in the United Network for Organ Sharing database from December 1, 1994, to May 31, 2009. RESULTS: In multivariable models conditioned on transplant center, patients with PSC were significantly more likely to receive a living donor transplant in both the pre-MELD (odds ratio [OR]=2.75; 95% confidence interval [CI], 2.20-3.44) and post-MELD eras (OR=4.08; 95% CI, 3.45-4.82). There was a significant interaction between PSC and post-MELD era of transplantation (OR=1.48; 95% CI, 1.11-1.97), indicating that patients with PSC were more likely to receive living donor transplants at baseline relative to patients without PSC, and that this effect was magnified following the introduction of the MELD score. CONCLUSIONS: These findings raise the possibility that allocating livers on the basis of MELD score may have yielded the unintended consequence of increasing rates for living donor transplants for patients with PSC relative to patients with other forms of end-stage liver disease. Future research is needed to determine whether the practice of selectively transplanting patients with PSC with living donor transplants is associated with differences in clinical outcomes.
Assuntos
Disparidades em Assistência à Saúde/tendências , Transplante de Fígado/tendências , Doadores Vivos/estatística & dados numéricos , Adulto , Distribuição de Qui-Quadrado , Colangite Esclerosante/diagnóstico , Colangite Esclerosante/cirurgia , Bases de Dados como Assunto , Feminino , Humanos , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Razão de Chances , Índice de Gravidade de Doença , Fatores de Tempo , Obtenção de Tecidos e Órgãos/estatística & dados numéricos , Estados Unidos , Listas de EsperaRESUMO
In the last few years, there have been developments In many aspects of liver transplantation. Improvements in surgical techniques and immunosuppression markedly increased the success rates of liver transplantation. This success has lead to increasing numbers of recipients. However, the availability of cadaveric organs for transplantation has not been changed in the last 10 years, resulting in a growing discrepancy between donors and recipients. Thus, it is necessary to properly select the best candidates for a successful liver transplant. This article will review the indications and contraindications for liver transplantation in the Model for End Stage Liver Disease (MELD) score era.
En los últimos años han existido avances importantes en el trasplante hepático. La evolución en la cirugía hepática y la aparición de mejores inmunosupresores han incrementado de manera importante el éxito en el trasplante hepático. Este éxito ha aumentado el número de receptores; sin embargo, al mismo tiempo el número de órganos ha permanecido estable en los últimos 10 años, teniendo como resultado un incremento en la disparidad entre donadores y receptores. Por lo tanto es necesario conocer quiénes son los mejores candidatos para un trasplante hepático. En este artículo se revisarán las indicaciones y contraindicaciones en el trasplante hepático en la era de la clasificación de MELD (por sus siglas en inglés Model for End Stage Liver Disease).
Assuntos
Humanos , Transplante de Fígado , Seleção de Pacientes , Colangite Esclerosante/cirurgia , Hepatite/cirurgia , Cirrose Hepática Biliar/cirurgia , Hepatopatias/cirurgia , Falência Hepática/cirurgia , Neoplasias Hepáticas/cirurgia , Transplante de FígadoRESUMO
OBJECTIVE: A comparison of the implications of the application of the principles of equity and efficiency as two desirable but competing attributes of the organ allocation system. Efficiency is defined in economic terms as the standard cost per QALY model and equity considerations are included in a model based on public preferences generated from a discrete choice experiment in determining priority for donor liver graft allocation. METHODS: A survey of the general public (n = 303) using a discrete choice experiment was undertaken. The results enabled estimation of the relative weights attached to several key factors which might be used to prioritise patients on the waiting list for liver transplantation. These weights were then used to develop a patient-specific index (PSI) for all patients diagnosed with one of three main chronic liver diseases who had received a liver transplant during an 18-month period at all Department of Health designated liver transplant centres in England and Wales (n = 207). The cost per QALY model comprised net total costs from assessment to 27 months following assessment as the numerator of the ratio. Net survival over the same time period, adjusted for HR-QOL using population values for the EQ-5D descriptive system, formed the denominator. RESULTS: Priority for liver transplantation differed markedly according to whether patients were ranked according to efficiency (net cost per QALY) or equity considerations (PSI) and the differences in ranks were found to be statistically significant (Wilcoxon signed rank test p < 0.001). CONCLUSIONS: This study emphasises that the priorities of the general public may not accord with those arising from a pure efficiency objective and quantifies the extent of the efficiency loss in terms of lost QALYs and increased net programme costs associated with the incorporation of equity concerns as reflected in public preferences for the allocation of donor livers for transplantation.
Assuntos
Atitude Frente a Saúde , Colangite Esclerosante/cirurgia , Análise Custo-Benefício , Prioridades em Saúde , Cirrose Hepática Alcoólica/cirurgia , Cirrose Hepática Biliar/cirurgia , Transplante de Fígado/estatística & dados numéricos , Anos de Vida Ajustados por Qualidade de Vida , Colangite Esclerosante/economia , Colangite Esclerosante/mortalidade , Doença Crônica , Eficiência Organizacional , Feminino , Humanos , Cirrose Hepática Alcoólica/economia , Cirrose Hepática Alcoólica/mortalidade , Cirrose Hepática Biliar/economia , Cirrose Hepática Biliar/mortalidade , Transplante de Fígado/economia , Masculino , Pessoa de Meia-Idade , Modelos Econométricos , Seleção de Pacientes , Alocação de Recursos , Justiça Social , Análise de Sobrevida , Reino Unido/epidemiologia , Listas de EsperaRESUMO
Liver transplantation has never been the subject of a randomized controlled trial, and there remains uncertainty about the magnitude of benefit and cost-effectiveness for specific patient groups. This article reports the results of an economic evaluation of adult liver transplantation in England and Wales. Patients placed on the waiting list for a liver transplant were observed over 27 months. The costs and health benefits of a comparison group, representing experience in the absence of liver transplantation, were estimated using a combination of observed data from patients waiting for a transplant and published prognostic models. The analysis focuses on three disease groups, for each of which prognostic models were available: primary biliary cirrhosis (PBC), alcoholic liver disease (ALD), and primary sclerosing cholangitis (PSC). A higher proportion of patients with ALD were assessed for a transplant but not placed on the waiting list. The estimated gain in quality-adjusted life-years from transplantation was positive for each of the disease groups. The mean incremental cost per quality-adjusted life-year (95% bootstrap confidence intervals) from time of listing to 27 months for patients with PBC, ALD, and PSC are pound 29,000 (pounds 1,000 to pounds 59,000), pounds 48,000 (pounds 12,000 to pounds 83,000) and pounds 21,000 (-pounds 23,000 to pounds 60,000), respectively. In conclusion, liver transplantation increases the survival and health-related quality of life of patients with each of three end-stage liver diseases. However, the extent of this increase differs between different disease groups. Cost-effectiveness estimates were poorer for patients with ALD over the 27-month period than for patients with PBC or PSC. This in part reflects the costs of the higher number of ALD patients assessed for each transplant.
Assuntos
Hepatopatias/cirurgia , Transplante de Fígado/economia , Avaliação de Resultados em Cuidados de Saúde/economia , Anos de Vida Ajustados por Qualidade de Vida , Adolescente , Adulto , Área Sob a Curva , Colangite Esclerosante/economia , Colangite Esclerosante/mortalidade , Colangite Esclerosante/cirurgia , Efeitos Psicossociais da Doença , Análise Custo-Benefício , Inglaterra/epidemiologia , Feminino , Humanos , Cirrose Hepática Biliar/economia , Cirrose Hepática Biliar/mortalidade , Cirrose Hepática Biliar/cirurgia , Hepatopatias Alcoólicas/economia , Hepatopatias Alcoólicas/mortalidade , Hepatopatias Alcoólicas/cirurgia , Masculino , Pessoa de Meia-Idade , Prognóstico , Modelos de Riscos Proporcionais , Obtenção de Tecidos e Órgãos , País de Gales/epidemiologiaRESUMO
OBJECTIVES: To determine the overall direct cost of liver transplantation in Canadian adults and to identify the factors that are associated with high cost. METHODS: The direct cost of liver transplantation from the perspective of third-party payers was determined in a retrospective analysis of data from hospital charts and databases. A consecutive series of 119 adults who underwent liver transplantation between 1991 and 1992 was followed from the date of listing for transplantation to the second anniversary of the transplant. Patient-specific services during the pre-transplantation, transplantation and post-transplantation phases were compiled and costed. The primary consideration was the impact of complications on the cost of transplantation. Secondary considerations were the impact of age, sex of the patient, diagnosis and severity of liver disease on the total cost. RESULTS: The overall mean measured cost of liver transplantation was Can$89,066 (range from Can$30,505-Can$690,431). The multivariate logistic regression model for overall costs revealed that severe liver disease (OR = 11.97), cytomegalovirus infection (OR = 6.12), additional operative procedure (OR = 4.22) and biliary complications (OR = 5.00) were associated with an increased likelihood of high cost. The addition of services that were not measured in the present analysis increased the total overall cost to a mean of $121,732 (1998 Canadian dollars, follow-up costs discounted and inflation adjusted). INTERPRETATION: The factors that were associated with high cost of liver transplantation in Canadian adults were advanced liver disease, postoperative cytomegalovirus infection, the requirement for additional operative procedures and biliary complications.
Assuntos
Custos Hospitalares , Transplante de Fígado/economia , Adolescente , Adulto , Idoso , Colangite Esclerosante/economia , Colangite Esclerosante/cirurgia , Efeitos Psicossociais da Doença , Infecções por Citomegalovirus/complicações , Feminino , Humanos , Cirrose Hepática/economia , Cirrose Hepática/cirurgia , Cirrose Hepática Biliar/economia , Cirrose Hepática Biliar/cirurgia , Hepatopatias/complicações , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , OntárioRESUMO
Issues in the selection and timing of liver transplantation for primary sclerosing cholangitis (PSC) remain controversial. Although the Child-Pugh classification (CP) score and Mayo PSC model have similar abilities to estimate pretransplantation survival, a comparison of these 2 scores in predicting survival after liver transplantation has not been conducted. The aim of this study is to compare the Mayo PSC model and CP score in predicting patient survival and related economic outcomes after liver transplantation. Data from 128 patients with PSC, identified from the NIDDK database, were used to calculate patient-specific Mayo PSC and CP scores before transplantation. Levels reflecting a poor outcome were defined a priori. Receiver operating characteristic (ROC) curves and regression methods (Cox proportional hazards and linear regression models) were used to assess the relationship between these 2 scores and 5 post liver transplantation outcome measures. CP score was found to be a significantly (P <.05) better predictor of death 4 months or less after liver transplantation than: (a) length of hospital stay >21 days (or death before discharge) and (b) resource utilization >200,000 units (measured by area under the ROC curve). The Cox model identified statistically significant (P <.05) associations between CP score and each outcome after adjusting for the Mayo PSC risk score. Similar results were not observed for the Mayo PSC model when adjusted for CP score. Among patients with PSC undergoing liver transplantation, CP score was a better overall predictor of both survival and economic resource utilization compared with the Mayo PSC model.
Assuntos
Colangite Esclerosante/cirurgia , Transplante de Fígado/economia , Adolescente , Adulto , Colangite Esclerosante/economia , Colangite Esclerosante/mortalidade , Custos e Análise de Custo , Feminino , Humanos , Unidades de Terapia Intensiva/economia , Tempo de Internação/economia , Transplante de Fígado/mortalidade , Masculino , Pessoa de Meia-Idade , Prognóstico , Modelos de Riscos Proporcionais , Estudos Prospectivos , Curva ROC , Índice de Gravidade de Doença , Taxa de SobrevidaRESUMO
BACKGROUND/AIM: It remains uncertain whether autoimmune hepatitis (AIH), as an original indication for orthotopic liver transplantation (OLTX), predisposes to the development of chronic rejection (CR) after surgery and published reports on heterogeneous groups of patients provided conflicting data. In this work we analyzed the incidence and risk factors for CR in a large cohort of adult patients transplanted for AIH in our unit. RESULTS: A total of 1190 adult patients received OLTX in our center between 1982 and 1998. A total of 77 patients (6.5%) were transplanted for AIH and 12 (15.6%) patients from this group developed clinical and histological features of CR within a median time of 3.5 months after OLTX. Patients with AIH who developed CR were younger than other AIH patients at OLTX (32 vs. 44.2 ys; P=0.015) and more often had histological features of moderate or severe acute rejection (83 vs. 34%; P=0.002) on early post-OLTX biopsies. The incidence of CR in AIH patients was significantly higher than in subjects transplanted for other indications such as primary biliary cirrhosis (8.2%; P<0.05), primary sclerosing cholangitis (5.2%; P<0.05) or alcoholic cirrhosis (2.0%; P<0.001). Also, we observed a tendency to decreased incidence of CR with time in all transplanted subjects. CONCLUSIONS: Apart from younger age at OLTX and higher incidence of severe acute rejection, patients with AIH who developed CR did not differ from other subjects transplanted for this indication. Unlike other studies, not stratified by diagnosis, recipient CMV negative status, young donor age, and HLA DR matching were not identified as risk factors for CR in AIH.
Assuntos
Doenças Autoimunes/cirurgia , Rejeição de Enxerto/etiologia , Hepatite/cirurgia , Transplante de Fígado/efeitos adversos , Adulto , Doenças Autoimunes/complicações , Colangite Esclerosante/cirurgia , Doença Crônica , Estudos de Coortes , Feminino , Hepatite/complicações , Hepatite Viral Humana/cirurgia , Humanos , Cirrose Hepática Biliar/cirurgia , Hepatopatias Alcoólicas/cirurgia , Masculino , Fatores de RiscoRESUMO
BACKGROUND: The possibility of primary sclerosing cholangitis (PSC) recurrence after liver transplantation has been debated. The aim of this study is to examine whether recurrent PSC and chronic rejection (CR) are different expressions of the same disease process. METHODS: One hundred consecutive patients receiving 118 grafts for the diagnosis of PSC were reviewed and placed into three groups: group A, recurrent disease, as evidenced by cholangiographic and pathologic findings with radiographic arterial flow to the liver (n=18; 15.7%); group B, those who developed CR (n=15; 13.0%); and group C, all others (n=82; 71.3%). Cholangiograms and histopathologic specimens were examined in a blinded fashion. RESULTS: Demographic factors were similar, except for age, with a significantly younger age and more episodes of rejection in groups A and B (P<0.03). Group A had a higher incidence of cytomegalovirus hepatitis (P=0.008). Five-year graft survivals for A, B, and C were 64.6%, 33.3%, and 76.1%, respectively (P=0.0001), 5-year patient survivals were 76.2%, 66.7%, and 89.1%, respectively (P=0.0001), and repeat transplantation rates were 27.8%, 46.7%, and 8.5%, respectively (P=0.005). Radiographically, 90% of cholangiograms in patients with recurrent disease showed at least multiple intrahepatic strictures. Histopathologically, patients with recurrent disease and CR shared many features. CONCLUSIONS: We have described a high incidence of recurrent PSC and CR in patients who received transplants for PSC. Histopathologic analysis suggests that CR and recurrent PSC could represent a spectrum of indistinguishable disease. However, the distinct difference in clinical outcome, as evidenced by an increased repeat transplantation rate and lower graft and patient survival in the CR group, clearly suggests that they are two distinct entities that require very different treatment strategies.
Assuntos
Colangite Esclerosante/cirurgia , Transplante de Fígado , Adulto , Colangiografia , Colangite Esclerosante/diagnóstico , Colangite Esclerosante/etiologia , Doença Crônica , Grupos Diagnósticos Relacionados , Resistência a Medicamentos , Feminino , Rejeição de Enxerto/patologia , Humanos , Transplante de Fígado/diagnóstico por imagem , Transplante de Fígado/imunologia , Transplante de Fígado/patologia , Masculino , Pessoa de Meia-Idade , Recidiva , Reoperação , Esteroides/farmacologia , Resultado do TratamentoRESUMO
Orthotopic liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis is a well-accepted therapy for complications of end-stage liver disease and is associated with an excellent outcome in the majority of cases. However, transplant centers are striving to improve on these outcomes by studying ways to optimize the timing of transplantation. Several natural history and prognostic models for both primary biliary cirrhosis and primary sclerosing cholangitis have been derived from the study of large populations of patients in an attempt to predict long-term rates of survival. In addition, models exist to predict resource utilization after liver transplantation. Other factors besides complications of end-stage liver disease may also be indications for transplantation, including refractory pruritus, recurrent bacterial cholangitis in patients with primary sclerosing cholangitis, hepatic osteodystrophy, and a poor quality of life.
Assuntos
Colangite Esclerosante/diagnóstico , Colangite Esclerosante/cirurgia , Cirrose Hepática Biliar/diagnóstico , Cirrose Hepática Biliar/cirurgia , Transplante de Fígado/métodos , Programas de Rastreamento/métodos , Colangite Esclerosante/epidemiologia , Doença Crônica , Feminino , Humanos , Cirrose Hepática Biliar/epidemiologia , Transplante de Fígado/efeitos adversos , Masculino , Prognóstico , Fatores de Risco , Taxa de Sobrevida , Resultado do TratamentoRESUMO
Orthotopic liver transplantation (OLT) has been shown to be effective in prolonging life and improving its quality in patients with end-stage liver disease. However, it remains one of the most expensive surgical procedures performed today. In an era when economic efficiency and financial accountability are being emphasized, it is imperative to consider resource utilization in evaluating candidates for OLT. We prospectively followed 106 patients who underwent OLT at the Mayo Clinic for primary biliary cirrhosis and primary sclerosing cholangitis between 1990 and 1994. Hospital and professional charges for the initial hospitalization were obtained on all patients. Univariate and multivariate models were constructed using preoperative clinical variables that had been previously found to be important in predicting clinical outcomes. The preoperative variables considered were age, gender, diagnosis of liver disease, Mayo risk score, Child's score, nutritional status, Karnofsky score, INR, serum levels of albumin, bilirubin, and creatinine, and the presence/absence of ascites, edema, encephalopathy, renal failure (serum creatinine >2.0) and gastrointestinal bleeding. Of the 106 patients, 3 were excluded from the analysis because they received multiple transplants during the initial hospitalization. Of the hospital charges we analyzed, the surgical fee for transplantation and donor acquisition expense were fixed in advance and, therefore, excluded. The following preoperative variables were found to be significant in the univariate analysis: Mayo risk score, Child's score, nutritional status, Karnofsky score, INR, serum levels of bilirubin and creatinine, presence of renal failure, and gastrointestinal bleeding. In the multivariate analyses, Karnofsky score of 40 or less was associated with a 48% increase in total charges. Poor nutritional status and renal failure were associated with a 34% and 31% increase, respectively. We identified 3 preoperative variables as significant independent predictors of resource utilization in liver transplantation. In an effort to maximize the economic efficiency with which liver transplantation is performed, we believe these factors should be taken into consideration in determining both the timing of transplantation and the suitability of potential transplant recipients.
Assuntos
Transplante de Fígado/economia , Adulto , Colangite Esclerosante/cirurgia , Custos e Análise de Custo , Feminino , Alocação de Recursos para a Atenção à Saúde , Preços Hospitalares , Humanos , Cirrose Hepática Biliar/cirurgia , Transplante de Fígado/estatística & dados numéricos , Masculino , Pessoa de Meia-Idade , Modelos Econômicos , Análise de RegressãoRESUMO
Recently three large studies have been presented in which the prognostic significance of clinical, laboratory and histological parameters measured early in the course of the disease was determined in primary sclerosing cholangitis patients. A different prognostic index was presented in each study. The aim of the present study was to evaluate these prognostic indices in a group of 37 patients with primary sclerosing cholangitis, assessed for liver transplantation. The results are compared to the outcome in the patients. At first referral, 12 patients were considered too healthy for transplantation and 17 were accepted for transplantation, six of whom died during the waiting time. Ten patients had cholangiocarcinoma or hepatocellular cancer. Albumin and bilirubin differed significantly between the patients accepted for transplantation and those considered too healthy. Only one prognostic index, presented by Dickson et al., could discriminate between "too healthy" and "in need of transplantation". However, the overlap between the groups was large, suggesting that this index may be of little or no help in the clinical situation with individual patients. Moreover, neither the prognostic index, nor any of the laboratory values could identify the patients with cancer. It is concluded that prognostic indicators have been found that may help to characterise primary sclerosing cholangitis patients. However, primary sclerosing cholangitis patients with an accompanying cholangiocarcinoma still cannot be identified.